Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?
Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP suddenly caught fire in late September 2025. On September 19, shares opened at a mere $0.08 but skyrocketed 98% by day’s end to $0.16, then jumped another 30% after-hours to ~$0.20 ts2.tech. This stunning one-day move – without any company-specific catalyst – was accompanied by an enormous volume of 705+ million shares traded ts2.tech. Market observers noted Adaptimmune as one of the top gainers that session despite the lack of fundamental news nasdaq.com ts2.tech. The rally appeared driven by renewed investor interest and speculation, not new data – a Nasdaq report bluntly stated “no company-specific news was released on September 19” to explain the surge nasdaq.com. Instead, retail traders and momentum algorithms seemed to pile in, possibly in a short-squeeze frenzy or simple fear of missing out.
